Holen Sie sich die Stockscreener-App
211.18
0.66%
-1.5498
Natera Inc Aktie (NTRA) Neueste Nachrichten
IVF Patients Say Natera Profited Off Ineffective Embryo Tests - Law360
Natera Adds Oncology Veterans Thomas Lynch and Eric Rubin to Board - citybiz
Natera adds two oncology experts to board of directors - Investing.com
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - Yahoo Finance
Did Supreme Court’s Refusal to Hear Natera Appeal Just Shift CareDx’s (CDNA) Investment Narrative? - simplywall.st
Natera expands Austin operations with new sequencing facility - MSN
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
NTRA Assumed by Wolfe Research -- Rating Upgraded to Outperform - GuruFocus
Wolfe Research initiates Natera stock coverage with outperform rating - Investing.com UK
Natera Inc stock (US6323071042): Wolfe Research initiation and recent price action in focus - AD HOC NEWS
Wolfe Research initiates Natera stock coverage with outperform rating By Investing.com - Investing.com South Africa
[144] Natera, Inc. SEC Filing - Stock Titan
NTRA (NASDAQ: NTRA) insider sells multiple lots, files to resell 3,000 shares - Stock Titan
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute - Reuters
U.S. Supreme Court rejects Natera, CareDx false-advertising dispute - TradingView
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial - Yahoo! Finance Canada
Natera And 2 Other Companies That May Be Trading Below Their Estimated Value - Yahoo Finance
Natera, Inc. (NTRA) Stock Analysis: Impressive Revenue Growth Amidst a Challenging Valuation Landscape - DirectorsTalk Interviews
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Is Natera (NTRA) Quietly Redefining Its Moat With MRD Trials And Sequencing Scale-Up? - Yahoo Finance
Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence - MedTech Dive
High Growth Tech Stocks in US for May 2026 - simplywall.st
Natera (NTRA) Partners with Diakonos Oncology for Melanoma Trial - GuruFocus
Natera, Diakonos Oncology Pair to Test Molecular Response in Refractory Melanoma Patients - Contract Pharma
Why Natera Is My Favorite Stock Idea for the Rest of 2026 - 24/7 Wall St.
Natera partners with Diakonos for melanoma therapy trial By Investing.com - Investing.com South Africa
Natera partners with Diakonos for melanoma therapy trial - Investing.com UK
Natera's Signatera Selected by Diakonos Oncology for Use in Melanoma Trial - Moomoo
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma - Yahoo Finance
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera president John Fesko sells $291,683 in shares By Investing.com - Investing.com India
Natera president sells $335,091 in company stock By Investing.com - Investing.com India
Natera president sells $335,091 in company stock - Investing.com UK
Natera president John Fesko sells $291,683 in shares - Investing.com
Natera (NTRA) president sells 1,652 shares to cover RSU tax obligations - Stock Titan
Natera (NTRA) president sells 1,438 shares to cover RSU tax withholding - Stock Titan
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions - The Globe and Mail
Natera Clinical Milestones Raise Questions On Growth Versus Valuation Risk - Sahm
Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300 - Moomoo
How Investors May Respond To Natera (NTRA) Boosting Panorama NIPT And Scaling Sequencing Capacity - simplywall.st
Natera (NTRA) Initiates Patient Enrollment for Early-Stage Breas - GuruFocus
Natera’s SIGNAL-ER 101 Study Assesses MRD Testing for ER+ Breast Cancer Treatment Decisions - geneonline.com
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer - The Malone Telegram
Baron Health Care Fund Q1 2026 Portfolio Activity - Seeking Alpha
Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results (NASDAQ:NTRA) - Seeking Alpha
3.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):